Abstract
Polycystic ovary syndrome (PCOS) is a complex reproductive and metabolic disorder affecting 10 % of reproductive-aged women, and is well associated with an increased prevalence of cardiovascular risk factors. However, there are few data concerning the direct association of PCOS with cardiac pathologies. The present study aims to investigate the changes in cardiac structure, function, and cardiomyocyte survival in a PCOS model, and explore the possible effect of calcitriol administration on these changes. PCOS was induced in C57BL/6J female mice by chronic dihydrotestosterone administration, as evidenced by irregular estrous cycles, obesity and dyslipidemia. PCOS mice progressively developed cardiac abnormalities including cardiac hypertrophy, interstitial fibrosis, myocardial apoptosis, and cardiac dysfunction. Conversely, concomitant administration of calcitriol significantly attenuated cardiac remodeling and cardiomyocyte apoptosis, and improved cardiac function. Molecular analysis revealed that the beneficial effect of calcitriol was associated with normalized autophagy function by increasing phosphorylation levels of AMP-activated protein kinase and inhibiting phosphorylation levels of mammalian target of rapamycin complex. Our findings provide the first evidence for the presence of cardiac remodeling in a PCOS model, and vitamin D supplementation may be a potential therapeutic strategy for the prevention and treatment of PCOS-related cardiac remodeling.
Similar content being viewed by others
References
M.O. Goodarzi, D.A. Dumesic, G. Chazenbalk, R. Azziz, Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat. Rev. Endocrinol. 7(4), 219–231 (2011). doi:10.1038/nrendo.2010.217
C.N. Jayasena, S. Franks, The management of patients with polycystic ovary syndrome. Nat. Rev. Endocrinol. 10(10), 624–636 (2014). doi:10.1038/nrendo.2014.102
H.S. Randeva, B.K. Tan, M.O. Weickert, K. Lois, J.E. Nestler, N. Sattar, H. Lehnert, Cardiometabolic aspects of the polycystic ovary syndrome. Endocr. Rev. 33(5), 812–841 (2012). doi:10.1210/er.2012-1003
H. Mani, M.J. Levy, M.J. Davies, D.H. Morris, L.J. Gray, J. Bankart, H. Blackledge, K. Khunti, T.A. Howlett, Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. 78(6), 926–934 (2013). doi:10.1111/cen.12068
P.C. de Groot, O.M. Dekkers, J.A. Romijn, S.W. Dieben, F.M. Helmerhorst, PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum. Reprod. Update 17(4), 495–500 (2011). doi:10.1093/humupd/dmr001
T. Oka, H. Akazawa, A.T. Naito, I. Komuro, Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114(3), 565–571 (2014). doi:10.1161/circresaha.114.300507
K. Lakhani, N. Constantinovici, W.M. Purcell, R. Fernando, P. Hardiman, Internal carotid artery haemodynamics in women with polycystic ovaries. Clin. Sci. (Lond.) 98(6), 661–665 (2000)
G. Masszi, E.M. Horvath, R. Tarszabo, R. Benko, A. Novak, A. Buday, A.M. Tokes, G.L. Nadasy, P. Hamar, Z. Benyo, S. Varbiro, Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS). PLoS One 8(3), e55589 (2013). doi:10.1371/journal.pone.0055589
S. Varbiro, L. Sara, P. Antal, A. Monori-Kiss, A.M. Tokes, E. Monos, R. Benko, N. Csibi, M. Szekeres, R. Tarszabo, A. Novak, P. Paragi, G.L. Nadasy, Lower-limb veins are thicker and vascular reactivity is decreased in a rat PCOS model: concomitant vitamin D3 treatment partially prevents these changes. Am. J. Physiol. Heart Circ. Physiol. 307(6), H848–H857 (2014). doi:10.1152/ajpheart.01024.2013
R. Calderon-Margalit, D. Siscovick, S.S. Merkin, E. Wang, M.L. Daviglus, P.J. Schreiner, B. Sternfeld, O.D. Williams, C.E. Lewis, R. Azziz, S.M. Schwartz, M.F. Wellons, Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women’s study. Arterioscler. Thromb. Vasc. Biol. 34(12), 2688–2694 (2014). doi:10.1161/atvbaha.114.304136
E.O. Talbott, D.S. Guzick, K. Sutton-Tyrrell, K.P. McHugh-Pemu, J.V. Zborowski, K.E. Remsberg, L.H. Kuller, Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20(11), 2414–2421 (2000)
S. Tepavcevic, D.V. Milutinovic, D. Macut, M. Stojiljkovic, M. Nikolic, I. Bozic-Antic, T. Culafic, J. Bjekic-Macut, G. Matic, G. Koricanac, Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome. Endocrine (2015). doi:10.1007/s12020-015-0558-1
S. Tepavčević, D.V. Milutinović, D. Macut, Z. Žakula, M. Nikolić, I. Božić-Antić, S. Romic, J. Bjekic-Macut, G. Matic, G. Korićanac, Dihydrotestosterone deteriorates cardiac insulin signaling and glucose transport in the rat model of polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 141, 71–76 (2014). doi:10.1016/j.jsbmb.2014.01.006
D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, W.P. Castelli, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322(22), 1561–1566 (1990). doi:10.1056/nejm199005313222203
N. Raja-Khan, J. Shah, C.M. Stetter, M.E. Lott, A.R. Kunselman, W.C. Dodson, R.S. Legro, High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil. Steril. 101(6), 1740–1746 (2014). doi:10.1016/j.fertnstert.2014.02.021
H. Selimoglu, C. Duran, S. Kiyici, C. Ersoy, M. Guclu, G. Ozkaya, E. Tuncel, E. Erturk, S. Imamoglu, The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J. Endocrinol. Invest. 33(4), 234–238 (2010). doi:10.3275/6560
T. Yao, X. Ying, Y. Zhao, A. Yuan, Q. He, H. Tong, S. Ding, J. Liu, X. Peng, E. Gao, J. Pu, B. He, Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy. Antioxid. Redox Signal. 22(8), 633–650 (2015). doi:10.1089/ars.2014.5887
M. Freundlich, Y.C. Li, Y. Quiroz, Y. Bravo, W. Seeherunvong, C. Faul, J.R. Weisinger, B. Rodriguez-Iturbe, Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am. J. Hypertens. 27(5), 720–726 (2014). doi:10.1093/ajh/hpt177
L.M. Meems, M.V. Cannon, H. Mahmud, A.A. Voors, W.H. van Gilst, H.H. Sillje, W.P. Ruifrok, R.A. de Boer, The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J. Steroid Biochem. Mol. Biol. 132(3–5), 282–289 (2012). doi:10.1016/j.jsbmb.2012.06.004
B.P. Rafacho, P. Santos, H.B. Assalin, L.P. Ardisson, M.G. Roscani, B.F. Polegato, F. Chiuso-Minicucci, A.A. Fernandes, P.S. Azevedo, M.F. Minicucci, L.A. Zornoff, S. Paiva, Role of vitamin D in the cardiac remodeling induced by tobacco smoke exposure. Int. J. Cardiol. 155(3), 472–473 (2012). doi:10.1016/j.ijcard.2011.12.078
A.S. Caldwell, L.J. Middleton, M. Jimenez, R. Desai, A.C. McMahon, C.M. Allan, D.J. Handelsman, K.A. Walters, Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 155(8), 3146–3159 (2014). doi:10.1210/en.2014-1196
E.L. van Houten, P. Kramer, A. McLuskey, B. Karels, A.P. Themmen, J.A. Visser, Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 153(6), 2861–2869 (2012). doi:10.1210/en.2011-1754
G. Masszi, A. Novak, R. Tarszabo, E.M. Horvath, A. Buday, E. Ruisanchez, A.M. Tokes, L. Sara, R. Benko, G.L. Nadasy, C. Revesz, P. Hamar, Z. Benyo, S. Varbiro, Effects of vitamin D3 derivative–calcitriol on pharmacological reactivity of aortic rings in a rodent PCOS model. Pharmacol. Rep. 65(2), 476–483 (2013)
Q. He, J. Pu, A. Yuan, W.B. Lau, E. Gao, W.J. Koch, X.L. Ma, B. He, Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia/reperfusion injury. Circ. Heart Fail. 7(6), 1032–1041 (2014). doi:10.1161/circheartfailure.114.001260
P. Shan, J. Pu, A. Yuan, L. Shen, L. Shen, D. Chai, B. He, RXR agonists inhibit oxidative stress-induced apoptosis in H9c2 rat ventricular cells. Biochem. Biophys. Res. Commun. 375(4), 628–633 (2008). doi:10.1016/j.bbrc.2008.08.074
J. Pu, A. Yuan, P. Shan, E. Gao, X. Wang, Y. Wang, W.B. Lau, W. Koch, X.L. Ma, B. He, Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur. Heart J. 34(24), 1834–1845 (2013). doi:10.1093/eurheartj/ehs011
A. Franczyk, K. Stolarz-Skrzypek, A. Wesolowska, D. Czarnecka, Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease. Cardiovasc. Hematol. Disord. Drug Targets 14(1), 34–44 (2014)
K. Yoneyama, O. Gjesdal, E.Y. Choi, C.O. Wu, W.G. Hundley, A.S. Gomes, C.Y. Liu, R.L. McClelland, D.A. Bluemke, J.A. Lima, Age, sex, and hypertension-related remodeling influences left ventricular torsion assessed by tagged cardiac magnetic resonance in asymptomatic individuals: the multi-ethnic study of atherosclerosis. Circulation 126(21), 2481–2490 (2012). doi:10.1161/circulationaha.112.093146
X. Xu, Y. Hua, S. Nair, R. Bucala, J. Ren, Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy. Hypertension 63(3), 490–499 (2014). doi:10.1161/hypertensionaha.113.02219
M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13(9), 1016–1023 (2011). doi:10.1038/ncb2329
N. Echeverry, G. Ziltener, D. Barbone, W. Weder, R.A. Stahel, V.C. Broaddus, E. Felley-Bosco, Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3 K/mTOR inhibitors. Cell Death Dis. 6, e1757 (2015). doi:10.1038/cddis.2015.124
A. Albu, S. Radian, S. Fica, C.G. Barbu, Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. Endocrine 48(2), 696–704 (2015). doi:10.1007/s12020-014-0340-9
B. Dilbaz, E. Ozkaya, M. Cinar, E. Cakir, S. Dilbaz, Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39(3), 272–277 (2011). doi:10.1007/s12020-011-9437-6
S. Wild, T. Pierpoint, H. Jacobs, P. McKeigue, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Cam) 3(2), 101–105 (2000)
S. Wild, T. Pierpoint, P. McKeigue, H. Jacobs, Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. 52(5), 595–600 (2000)
F. Orio Jr, S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, A. Colao, The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696–3701 (2004). doi:10.1210/jc.2003-032049
G. Muscogiuri, V. Nuzzo, A. Gatti, A. Zuccoli, S. Savastano, C. Di Somma, R. Pivonello, F. Orio, A. Colao, Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes? Endocrine (2015). doi:10.1007/s12020-015-0609-7
S.E. Judd, S.N. Raiser, M. Kumari, V. Tangpricha, 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J. Steroid Biochem. Mol. Biol. 121(1–2), 445–447 (2010). doi:10.1016/j.jsbmb.2010.04.013
H.U. Simon, Autophagy in myocardial differentiation and cardiac development. Circ. Res. 110(4), 524–525 (2012). doi:10.1161/circresaha.112.265157
M. Xie, Y. Kong, W. Tan, H. May, P.K. Battiprolu, Z. Pedrozo, Z.V. Wang, C. Morales, X. Luo, G. Cho, N. Jiang, M.E. Jessen, J.J. Warner, S. Lavandero, T.G. Gillette, A.T. Turer, J.A. Hill, Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 129(10), 1139–1151 (2014). doi:10.1161/circulationaha.113.002416
J. Moscat, M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137(6), 1001–1004 (2009). doi:10.1016/j.cell.2009.05.023
J.T. Fassett, X. Hu, X. Xu, Z. Lu, P. Zhang, Y. Chen, R.J. Bache, AMPK attenuates microtubule proliferation in cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 304(5), H749–H758 (2013). doi:10.1152/ajpheart.00935.2011
Z. Xie, K. Lau, B. Eby, P. Lozano, C. He, B. Pennington, H. Li, S. Rathi, Y. Dong, R. Tian, D. Kem, M.H. Zou, Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60(6), 1770–1778 (2011). doi:10.2337/db10-0351
Q.D. Zhao, S. Viswanadhapalli, P. Williams, Q. Shi, C. Tan, X. Yi, B. Bhandari, H.E. Abboud, NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 131(7), 643–655 (2015). doi:10.1161/circulationaha.114.011079
T.S. Lisse, T. Liu, M. Irmler, J. Beckers, H. Chen, J.S. Adams, M. Hewison, Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 25(3), 937–947 (2011). doi:10.1096/fj.10-172577
G. Wu, Y. Liu, H. Huang, Y. Tang, W. Liu, Y. Mei, N. Wan, X. Liu, C. Huang, SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload. Cardiovasc. Res. 107(2), 203–215 (2015). doi:10.1093/cvr/cvv170
Acknowledgments
This work was supported by Grants from the National Basic Research Program of China (No. 2012CB944900), the National Science and Technology Support Program (No. 2012BAI32B01), Natural Science Foundation of China (Nos. 31171444, 30973209 and 81270708), and Major Scientific and Technological Special Focus on Social Development Project of the Science and Technology Department of Zhejiang province (No. 2010C13028).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gao, L., Cao, JT., Liang, Y. et al. Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome. Endocrine 52, 363–373 (2016). https://doi.org/10.1007/s12020-015-0797-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0797-1